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ABSTRACT: Delivering therapeutics to the posterior segment of
the eye is challenging due to various anatomical and physical
barriers. While signiﬁcant improvements have been realized by
introducing direct injections to diseased sites, these approaches
come with potential side eﬀects that can range from simple
inﬂammation to severe retinal damage. The topical instillation of
drugs remains a safer and preferred alternative for patients’
compliance. Here, we report the synthesis of penetratin-complexed,
redox-responsive hyaluronic acid-based nanogels for the triggered
release and delivery of therapeutics to the posterior part of the eye
via topical application. The synthesized nanogels were shown to
release their load only when exposed to a reducing environment, similar to the cytoplasm. As a model drug, visual chromophore
analog, 9-cis-retinal, was loaded into nanogels and eﬃciently delivered to the mouse retina’s photoreceptors when applied topically.
Electroretinogram measurements showed a partial recovery of photoreceptor function in all treated eyes versus untreated controls.
To the best of our knowledge, this report constitutes the ﬁrst attempt to use a topically applied triggered-release drug delivery system
to target the pigmented layer of the retina, in addition to the ﬁrst attempt to deliver the visual chromophore topically.

1. INTRODUCTION
The eye’s posterior side includes the sclera, the retina, choroid,
the optic nerve, and the vitreous humor. This part of the eye
can be aﬀected by many disorders and diseases that may result
in irritation, visual impairment, and even vision loss, such as
glaucoma, age-related macular degeneration, and retinopathy.1
Relevant to this study, inherited retinal degenerative diseases
are a group of disorders that aﬀect the normal function of the
retinal photoreceptor cells and are considered a major cause of
vision loss.2 A signiﬁcant fraction of these disorders is related
to photoreceptors’ inability to capture light and generate
electric signals to be processed by the brain in a cascade of
successive and complex events that are known as phototransduction.3 Brieﬂy, light photons are absorbed by visual
pigments that consist of the chromophore 11-cis-retinal
conjugated to the protein opsin in photoreceptor discs.
Consequently, 11-cis-retinal is photoisomerized to all-transretinal, switching the visual pigment to its physiologically active
state. Retinal is eventually released from opsin and reduced to
the more soluble all-trans-retinol. The retinol is then recycled
back to 11-cis-retinal in a process referred to as the visual cycle,
which is required for the ability of photoreceptors to detect
light continuously.4 Paramount to the classic visual cycle is
retinal pigmented epithelium (RPE) cells that enzymatically
convert all-trans-retinol to 11-cis-retinal and supply photoreceptors with this visual chromophore.5 In the RPE cells,
chromophore regeneration relies on two important enzymes:
lecithin-retinol acyltransferase (LRAT) and 65 kDa retinoid
© 2021 The Authors. Published by
American Chemical Society

isomerase (RPE65); the lack of either of them has been linked
to unavailability of 11-cis-retinal resulting in the impairment of
photoreceptor function and retinal degeneration.6−8 Inherited
retinal degenerations are currently incurable; however, treatments that attempt to control the progress of the disease are
available, such as gene augmentation therapy for RPE65 gene
mutation-related diseases.9−12 A diﬀerent proposed treatment
that has shown promise can be achieved by supplying the
retina with exogenous cis-retinoids to bypass the visual cycle
and regenerate visual pigments.13−19 Nevertheless, the success
of any approach is strongly dependent on devising optimized
delivery systems that can solely deliver the chromophore to its
target site. Furthermore, the optimal method for chromophore
delivery must cause minimal to no side eﬀects to prompt
patients’ compliance.
Van Hooser et al.17 studied the eﬀects of intravenous
injection of 9-cis-retinal and observed that the disease
progression was disrupted, and even some degeneration eﬀects
were reversed. More importantly, the eﬀect was shown to last
for more than 6 months. However, the disadvantage of this
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Figure 1. Synthesis steps for the preparation of HA−cys−CH conjugate.

patients’ compliance. Nevertheless, the use of drug instillation
constitutes a signiﬁcant challenge as drug delivery is hindered
by physiological and anatomical barriers inside the eye.23,24
Drug administration via the concept of targeted delivery is
widely acknowledged because of its ability to mediate
equilibrium between the therapeutic eﬀects and side eﬀects
of a drug. For that purpose, polymer-based nanogels have been
used for decades for various applications. One particular
material is redox-responsive nanogel, where the drug is
released in a reducing environment.25

method is the possibility of rapid clearance of the
chromophore by the kidneys, which requires the injection of
large doses, raising the prospect of infection and toxicity. The
same concern is expressed when cis-retinoids are delivered via
intravitreal injection. The needed frequent injections to
maintain the level of the retinoid, in this case, can also lead
to complicated side eﬀects.20−22
Because the treatment of inherited retinal degenerations
caused by retinal deﬁciency requires an ongoing long-term
administration of the visual chromophore, a topical application
would be the most preferred method for safety reasons and
6173

https://dx.doi.org/10.1021/acsomega.0c05535
ACS Omega 2021, 6, 6172−6184

ACS Omega

http://pubs.acs.org/journal/acsodf

Article

Figure 2. Physical characteristics of nanogel’s (A) size and (B) ζ potential at diﬀerent stages of synthesis and drug loading steps.

Here, we report our ﬁrst attempt to deliver the visual
chromophore chemical analog, 9-cis-retinal, to photoreceptor
cells of the retina via its topical application using penetratincomplexed, redox-responsive nanogels. The nanogels were
formed immediately upon dispersion of hyaluronic acid−
cystamine−cholesterol (HA−cys−CH) conjugate in deionized
(DI) water. HA is a natural ligand for the cluster of
diﬀerentiation 44 (CD44)26 cell membrane receptors, which
were shown to be expressed on the surface of RPE and Muller
cells of the retina in vertebrates.27,28 To track their destination,
nanogels were covalently tagged with ﬂuorescein. Finally,
nanogels were loaded with 9-cis-retinal, and their delivery to
mouse photoreceptors was studied both in retinal explants (ex
vivo) and in vivo.

with disulﬁde bonds that are susceptible to reduction. This
property makes redox-sensitive nanogels particularly attractive
due to the existence of substantial redox potential diﬀerence
between the extracellular environment and the more reducing
environment of the cytoplasm and cell nucleus.35 Furthermore,
the synthesized nanogels are made of hyaluronic acid. Using
HA is intended to enhance biocompatibility, cellular uptake,
drug solubility, and speciﬁc retina targeting via CD44 cell
receptors.36 The prepared HA−cys−CH conjugate can form
nanogels immediately upon dispersion in DI water. The size
and ζ potential of the formed nanogels at various steps were
investigated by dynamic light scattering (DLS) (Figure 2) and
transmission electron microscopy (Figure S2). The formed
nanogels exhibited a small particle size with a single peak at
around 80 nm, which indicates an absence of aggregation.
Upon cross-linking of the nanogels, however, the size of the
nanogels decreased as the nanogel’s structure became compact
(Figure S3), but ﬁnally increased after drug loading, reaching a
ﬁnal size of 68 nm. For an eﬃcient delivery to the retina,
nanogel’s size has to be large enough to avoid clearance
through blood vessels and small enough to seep through
various eye barriers.37 In addition to their small size, the ζ
potential changed from −7.56 to −2.24 mV after penetratin
complexation due to its cationic character. It can be concluded
that the nanogels’charge was not aﬀected by drug loading.
Nanoparticles’ behavior, including their stability and toxicity in
living systems, is tightly related to their surface properties,
particularly to the ζ potential, for which positive values predict
higher interactions with living systems, and consequently,
potentially higher toxicity.38 In our case, ζ potential measurements were done at pH 7.4, which mimics the cytoplasm
environment (pH ∼ 7.2), and the synthesized nanogels were
negatively charged because of the ionized carboxylic groups of
HA at this pH.
2.2. Release Proﬁle of Loaded Nanogels. Initially,
nanogels were loaded with ﬂuorescein as a model hydrophobic
molecule, followed by cross-linking using a thiol−disulﬁde
exchange reaction.39−41 The working mechanism of nanogels’
self-assembly, covalent cross-linking, and drug release is
illustrated in Scheme S1. Adding a catalytic amount of 1,4dithiothreitol (DTT) to the self-assembled nanogels results in
HA chains cross-linking through the thiol−disulﬁde exchange
reaction. Eventually, when a high concentration of DTT is
added, the covalent cross-links between HA chains break,
resulting in load release. The ﬂuorescein release proﬁle was

2. RESULTS AND DISCUSSION
2.1. Synthesis of Hyaluronic Acid−Cystamine−Cholesterol Conjugate (HA−Cys−CH). Redox-responsive nanogels were prepared via a two-step synthesis. In the ﬁrst step,
cholesteryl chloroformate, via its acyl chloride, was reacted
with the primary amine group of cystamine free base to yield
amine-terminated cholesterol. The second step consisted of
conjugating the amine-terminated cholesterol, via its primary
amine groups, to the carboxylic groups of hyaluronic acid using
an N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) coupling protocol (Figure 1).
The 1H NMR spectroscopy conﬁrmed the successful
conjugation of cystamine-modiﬁed cholesterol to hyaluronic
acid (Figure S1). The NMR spectrum contained the
characteristic peaks of cholesterol between 0.5 and 1.8 ppm.
Furthermore, the peak at 5.3 ppm was ascribed to the alkene
group of cholesterol. In the same spectrum, HA characteristic
peaks were shown between 3.5 and 4.5 ppm. Using the same
NMR spectrum, the number of conjugated cholesterol to HA
was estimated to be eight cholesterol moieties per chain of HA.
Modifying HA with the hydrophobic cholesterol moiety leads
to modifying its physicochemical properties, including its
solubility. This modiﬁcation can, therefore, be exploited by
loading an appropriately hydrophobic drug for pharmaceutical
applications.29−33 Stimuli-responsive nanocarriers are widely
recognized due to their advantages over traditional nanocarriers in drug delivery.34 These responsive nanocarriers can
undergo physical or chemical changes to respond to externally
applied stimuli, making them good candidates to address the
drawbacks of drugs’ nonselectivity. Our nanogels are endowed
6174
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Figure 3. (A) Triggered-release proﬁle of ﬂuorescein from the redox-sensitive HA−cys−CH and HA−cys−CH/P nanogels showing that the
presence of 10 mM DTT causes the disintegration of covalent cross-links of nanogels to release their load. (B) Change of nanogel’s size by DLS in
response to 10 mM DTT.

Figure 4. Real-time monitoring of cell attachment behavior using ECIS in response to HA−cys−CH and HA−cys−CH/P exposure. The HA-based
nanogels were biocompatible with ARPE-19 cells at the exposure concentrations of 1 mg/mL and below.

studied at pH 7.4 and 37 °C in the presence or absence of 10
mM DTT. As shown in Figure 3A, a negligible ﬂuorescein
release from cross-linked nanogels was detected in the absence
of a reducing environment. When nanogels were dispersed in
10 mM DTT, however, ﬂuorescein release was immediate and
quantitative, indicating that drug release is sensitive to the
intracellular reductive environment. To further illustrate the
sensitivity of the cross-linked nanogels to a redox environment,
the change of their size was observed in the presence and
absence of 10 mM DTT. Twenty-four hours after incubation,
the size of the cross-linked nanogels was observed to decrease
to less than 30 nm, mirroring the disintegration of nanogels’
structure in a reducing environment. In the absence of DTT,
however, the change in particle size was insigniﬁcant (Figure
3B). It is to be noted that the redox sensitivity of the nanogels
was not aﬀected by their complexation by the cell-penetrating
peptide penetratin. The reduction-triggered release of these

nanogels is an important property that will translate into
eﬃcient drug delivery inside the target cells. It is worth noting
that the release time of ﬂuorescein from the cross-linked
nanogels reﬂects both the responsiveness time of the nanogels
and the diﬀusion time of ﬂuorescein through the dialysis
membrane.
2.3. Biocompatibility Assessment of the Nanogels by
Electrical Cell−Substrate Impedance Sensing (ECIS)
Analysis. The attachment of ARPE-19 cells in the presence
of HA−cys−CH was monitored through electrical cell−
substrate impedance sensing (ECIS) analysis in real time. As
seen in Figure 4, the cell detachment amount, which
corresponds to higher cytotoxicity, increased as the nanogel
exposure concentration increased. According to the results
obtained above 0.5 mg/mL, cell growth was signiﬁcantly
hindered for HA−cys−CH and HA−cys−CH/P. The ARPE19 cells started to detach from the plate almost immediately
6175
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Figure 5. Confocal microscopy images of ARPE-19 cells exposed to 2 mg/mL carbon dot-conjugated nanogels (A) without and (B) with
penetratin at 30 min, 1 h, 2 h, and 4 h. Penetratin coating signiﬁcantly increased the intracellular concentration of the nanogels.

distribution in the posterior part of the eye even when applied
topically. In this study, to assess the extent of the cellular
uptake of the nanogels, and for the in vitro imaging, ARPE-19
cells were used. Carbon dots (CD) with a diameter of less than
5 nm were here used for labeling purposes as we previously
reported.49 As seen in Figure 5, cellular uptake was observed to
increase with a longer incubation time for nanogels both with
and without penetratin complexation. Within the studied time,
the maximum signal was reached after 4-h incubation.
Nanogels interact with cells according to their surface
functionalization. ARPE-19 cells have a high density of
CD44 receptors; we previously showed that coating nanoparticles of higher than 50 nm diameter with hyaluronic acid
leads to their eﬃcient uptake by ARPE-19 cells via CD44
receptor-mediated endocytosis.42 When nanogels were complexed with penetratin, however, the ﬂuorescence intensity
increased, indicating their higher cellular internalization as
compared to that for non-penetratin-complexed nanogels.
2.5. Administration of 9-cis-Retinal-Loaded Nanogels
to Photoreceptors in Isolated Retinas of Rpe65−/− Mice.
An eﬃcient enzymatic reisomerization of the chromophore in
RPE cells as a part of the canonical visual cycle and its
subsequent supply to retinal photoreceptors are essential for
absorbing the light and transduce the visual signal constantly.
To establish the principle applicability of our designed
nanogels for the delivery of cis-retinoids to photoreceptors in
mice, we took advantage of the RPE65-deﬁcient mouse line, a
widely accepted model of human Leber congenital amaurosis
type 2 (LCA2) retinal disease. While most cone photoreceptors die within the ﬁrst 3 weeks in Rpe65−/− animals, due

following the exposure to a concentration of 4 mg/mL of
nanogels. Overall, all three concentration levels above 0.5 mg/
mL; 1, 2, and 4 mg/mL caused a signiﬁcant decrease in the cell
impedance recordings in the ﬁrst ∼6 h following the exposure
to nanogels. After the sixth hour, the cells started to recover;
however, only the cells exposed to 1 mg/mL of HA−cys−CH
and 0.5 mg/mL of HA−cys−CH/P could recover completely
(reached the same impedance level as control cells).
Previously, we showed that the HA coating on nanoparticles
not only assists nanoparticle’s internalization but also protects
the cells from reactive oxygen species (ROS) damage.42 The
cytotoxicity observed at higher concentrations is probably due
to the high accumulation of cholesterol and formation of
needle-shaped crystals,43 as a result of the disulﬁde bond
breaking between hyaluronic acid and cholesterol in the
reducing environment inside the cells. Furthermore, higher free
cholesterol levels above the physiological concentration are
likely to halt the formation of membrane domains.44 On the
other hand, penetratin complexation seems to increase the
toxicity of the nanogels. While previous studies have already
shown that penetratin does not aﬀect cell viability,45,46
including for ocular applications,47 in our case, the increase
in toxicity is likely due to increased cellular uptake of HA−
cys−CH/P versus HA−cys−CH.
2.4. Cellular Uptake of Nanogels. Next, we studied the
time-dependent cellular internalization of nanogels that were
either modiﬁed or not modiﬁed with penetratin. This cellpenetrating peptide has been previously used to enhance
ocular permeability and drug targeting to the retina.47,48
Penetratin-complexed HA was shown to have a good
6176
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Figure 6. Acute treatment with nanogels loaded with 9-cis-retinal largely restores the amplitude and sensitivity of chromophore-deﬁcient mouse
photoreceptors ex vivo. (A) Representative family of transretinal rod ERG responses from Rpe65−/− mouse retinas. Test ﬂashes of 505 nm light with
intensities of 5.7 × 104, 2.0 × 105, 6.0 × 105, 2.0 × 106, and 5.7 × 106 photons/μm2 were delivered at time 0. (B) Representative family of
transretinal rod ERG responses from Rpe65−/− mouse retinas treated with HA−cys−CH nanogels loaded with 9-cis-retinal in the presence of
penetratin. Test ﬂashes of 505 nm light with intensities of 14, 33, 114, 392, 1.2 × 103, 3.9 × 103, and 1.1 × 104 photons/μm2 were delivered at time
0. (C) Representative family of transretinal rod ERG responses from Rpe65−/− mouse retinas treated with 9-cis-retinal only. Test ﬂashes of 505 nm
light with the same intensities as in (B) were delivered at time 0. (D) Averaged rod intensity−response functions (mean ± scanning electron
microscopy (SEM)) for untreated Rpe65−/− isolated retinas (n = 4) and Rpe65−/− retinas treated either with HA−cys−CH nanogels loaded with 9cis-retinal in the presence of penetratin (n = 3) or free 9-cis-retinal in the media (n = 7). Error bars for some points are smaller than the symbol size.
Hyperbolic Naka-Rushton ﬁts yielded half-saturating intensities (I1/2) of 4.7 × 105, 175, and 142 photons/μm2.

(such as ERG b-wave driven by ON bipolar cells),55 thus
allowing us to isolate the photoreceptor-driven component of
the ERG photoresponse (Figure 6). Because mouse M-cones
in the Rpe65−/− line produce negligible light responses to
green light after 3 weeks of age due to their rapid
degeneration,54 we assumed that essentially all responses in
6-week-old RPE65-deﬁcient animals we used in this study were
generated by rods. As expected, chromophore-deﬁcient rods in
control untreated Rpe65−/− mice exhibited very small
responses to test ﬂashes of green light (Figure 6A) and were
desensitized by >2000-fold as compared with those from
typical wild-type animals (Figure 6D, black symbols), as
reported earlier.54,56 The administration of nanogels loaded
with 9-cis-retinal in the presence of penetratin eﬀectively
restored the rod response amplitude (Figure 6B) and
sensitivity in this mouse model (Figure 6D, red symbols).
The extent of rod resensitization was comparable to that
observed upon treatment of Rpe65−/− retinas with pure 9-cisretinal dissolved in the incubation media (Figure 6C,D, gray
symbols), and it remained only ∼4 times lower than the
sensitivity of wild-type mouse rods.54 The bulk of the latter
diﬀerence is likely due to the 3-fold lower quantum eﬃciency
of vertebrate isorhodopsin (a pigment formed with 9-cisretinal) compared to rhodopsin, in which opsin is bound to
native 11-cis-retinal.57 These results demonstrate the applicability of HA−cys−CH nanogels for chromophore delivery to

to a greatly impaired RPE visual cycle resulting in misfolding
and mislocalization of cone opsins,50−52 the rods in this strain
do not degenerate appreciably until about 7 weeks of age.53
Importantly for our study, rods in these mice are mostly devoid
of the chromophore and, as a result, highly desensitized.
However, their function can largely be restored with the
application of exogenous retinoids.16,17,54
Similarly to ﬂuorescein, a commercially available analog of
the visual chromophore, 9-cis-retinal, was loaded into HA−
cys−CH nanogels followed by cross-linking. The loading
content was estimated by UV−vis spectroscopy (after
determining λmax = 378 nm of 9-cis-retinal in dimethyl
sulfoxide (DMSO)). Using a standard curve of various
concentrations of this retinoid in DMSO, the loading content
was quantiﬁed to be 18.7%. The eﬃcacy of nanogel-driven
administration of 9-cis-retinal was next examined in isolated
retinas of chromophore-deﬁcient mouse line lacking RPE65
protein (Rpe65−/−), using a method similar to the one for the
acute delivery of 9-cis-retinal established by us previously.54
After reaching and penetrating photoreceptor outer segments
(POS), the cross-linked nanogels are expected to release their
9-cis-retinal upon reduction of the disulﬁde bond by intracellular glutathione, and the retinoid would then recombine
with free opsin in the discs to regenerate the visual pigment.
Transretinal (ex vivo) electroretinogram (ERG) recordings
were performed in the presence of postsynaptic inhibitors
blocking contributions of higher-order response components
6177
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ﬂuorescein HA−cys−CH nanogels (Figure 7D), which further
highlights the role of the cell-penetrating peptide to enhance
cellular uptake of the nanogels. The RPE cell layer is a single
layer that is located next to the photoreceptor cells. Because its
dysfunction may lead to visual impairment, RPE cells are often
the target of treating ocular diseases.58 Therefore, the
distribution of nanogels in RPE cells opens a potential for
new, more convenient approaches to treat ocular diseases by
simple topical application.
It is noteworthy to mention that there are two possible ways
the drug delivery systems can reach the retina upon instillation:
either through the cornea vitreous or the conjunctival−scleral
routes. The latter route, however, is likely the dominant path,
as reported previously.59 Furthermore, the physical characteristics of our drug delivery system, including its relatively small
size, negative surface charge, and hydrophilicity, likely
facilitated the nanogels to cross through the porous, hydrophilic, negatively charged scleral constituents.60 It is also worth
mentioning that the increased ﬂuorescence signal in the RPE
layer is consistent with the higher expression of CD44 cell
receptors in these cells compared to others, for which
hyaluronic acid is a ligand.27
2.7. Topical Application of 9-cis-Retinal-Loaded
Nanogels to Mouse Eyes. Finally, we examined the
possibility of delivering the visual chromophore to photoreceptors in vivo with the topical application of penetratincomplexed HA−cys−CH nanogels loaded with 9-cis-retinal
within a 2 h therapeutic window. During this period, the
application of the compound mixture to the right eye of the
live anesthetized mouse was repeated three times (see
Materials and Methods), and the left (control) eye received
the equivalent volume of PBS solution. This procedure
improved the experimental outcome compared to a single
drug application, as was established in preliminary tests. The
experiment was followed by standard ERG recordings from
these animals (Figure 8).
First, we conﬁrmed that photoreceptors (likely, predominantly rods) in 6-week-old Rpe65−/− mice indeed responded
to bright light in vivo, even in the absence of the chromophore.
They generated typical ERG responses with the initial negative
component (rod-driven ERG a-wave) followed by larger
positive ERG b-wave driven by rod ON bipolar cells. As in
the case of transretinal recordings (Figure 6), the magnitudes
of both a- and b-wave ERG components in these animals were
several-fold lower than those in wild-type mice with a normally
operating RPE visual cycle, and their photosensitivity was
reduced dramatically as well. Notably, we found that the
topical treatment with 9-cis-retinal-loaded nanogels in the
presence of penetratin increased maximal response amplitudes
of both ERG a- and b-waves in respective eyes by 40−50%.
However, the eﬀect was statistically signiﬁcant (P < 0.01) only
at the brightest light intensity (700 cd s/m2) produced by our
ERG apparatus (Figure 8A,B). The rod sensitivity of drugtreated mice remained unchanged. In the absence of
penetratin, topically applied 9-cis-retinal-loaded nanogels
were ineﬀective for restoration of rod responses in live
Rpe65−/− mice (Figure 8C,D), as was 9-cis-retinal alone
(Figure 8E,F). These results clearly highlight the role of
penetratin in our drug delivery system in improving drug
bioavailability through the enhancement of nanogel transport
via the various ocular barriers.
Despite the partial recovery of photoreceptor function in the
presence of 9-cis-retinal chromophore delivered by our

photoreceptor cells in retinal explants and its ability to drive
rod visual pigment regeneration.
2.6. Topical Application of Fluorescein-Conjugated
Nanogels to Mouse Eyes. The ultimate goal of this study
was to develop a reliable noninvasive method for nanoparticlemediated delivery of cis-retinoids and, eventually, other ocular
drugs to retinal photoreceptors in vivo via topical administration. As a test approach, some of our HA−cys−CH
nanogels were covalently conjugated with ﬂuorescein to trace,
by immunohistochemistry, the distribution of the label in the
retina and RPE after their topical application to mouse eyes. As
expected, no ﬂuorescence was detected in the control sample
of phosphate-buﬀered saline (PBS)-treated or ﬂuoresceintreated eyes (Figure 7A,B). Due to its hydrophobicity, free

Figure 7. Confocal microscopy images of retinal cross sections after
topical application of (A) PBS buﬀer, (B) ﬂuorescein-only, (C)
ﬂuorescein-labeled nanogels without penetratin, and (D) ﬂuoresceinlabeled-nanogels with penetratin complexation. The presence of the
nanogels can be seen in the marked section. RPE, retinal pigmented
epithelium; POS, photoreceptor outer segments; ONL, outer nuclear
layer; and INL, inner nuclear layer. Scale bars are 20 μm. The sections
are stained only for 4′,6-diamidino-2-phenylindole (DAPI), the
nucleus staining (blue). Green particles are the ﬂuorescein-labeled
nanogels.

ﬂuorescein could not cross the various ocular barriers. In
contrast, hyaluronic acid-based nanogels were able to reach the
RPE cells as evidenced by detection of the ﬂuorescence signal
at the RPE layer, but not in any of the retinal layers of eyes
treated with ﬂuorescein HA−cys−CH nanogels (Figure 7C). A
robust ﬂuorescence signal from nanogels was, however, more
visible in the RPE layer treated with penetratin-complexed
6178
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Figure 8. Topical application of nanogels loaded with 9-cis-retinal partially restores ERG a-wave and b-wave responses of chromophore-deﬁcient
mice in the presence of the penetratin peptide in vivo. (A, B) Averaged rod (scotopic) intensity−response functions (mean ± SEM) for control
untreated Rpe65−/− mouse left eyes (n = 8) and right eyes of the same animals treated with HA−cys−CH nanogels loaded with 9-cis-retinal in the
presence of penetratin (n = 8). (C, D) Lack of response recovery in the absence of penetratin. Averaged rod intensity−response functions (mean ±
SEM) for control untreated Rpe65−/− mouse left eyes (n = 6) and right eyes of the same animals treated with HA−cys−CH nanogels loaded with
9-cis-retinal in the absence of penetratin (n = 6). (E, F) Lack of response recovery after topical application of the visual chromophore alone.
Averaged rod intensity−response functions (mean ± SEM) for control untreated Rpe65−/− mouse left eyes (n = 5) and right eyes of the same
animals treated with 9-cis-retinal only (n = 5). Error bars for some points in all panels are smaller than the symbol size. Statistical signiﬁcance of the
data is presented as **P < 0.01.

3. CONCLUSIONS

penetratin-assisted nanogels in vivo, the procedure is currently
under further optimization to overcome several possible
physical barriers imposed by the cornea of the eye and its
intraocular environment. It should also be noted that the local
concentration of opsins in native vertebrate photoreceptor disc
membranes is exceptionally high (up to 5 mM).61 This dictates
the need for further improving the eﬃciency of nanogel
loading with retinoids available for release and eventual
pigment regeneration. Yet, the eﬃcient delivery of other
therapeutic-loaded HA−cys−CH/P nanogels, eﬀective at
smaller therapeutical dosages, to the RPE may not require
such large loads.

The present work reports the synthesis of redox-responsive
hyaluronic acid-based nanogels that are complexed with
penetratin to deliver therapeutics to the posterior segment of
the eye. Upon their topical application, the nanogels can reach
the RPE cells and deliver their load in response to the cells’
reducing environment. As a proof of concept, the visual
chromophore analog, 9-cis-retinal, was loaded into the HAbased nanogels and showed robust recovery of photoreceptor
function when applied to isolated retinas and a partial recovery
of photoreceptor function in all treated eyes compared to
untreated controls after topical application in vivo. Though the
procedure requires further optimization, the drug delivery
system reported here constitutes a promising alternative to
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was opaque upon addition of CH−cys, was stirred at RT for 6
h, followed by puriﬁcation by centrifugation to remove the
precipitates. The supernatant was dialyzed against DI water,
and the ﬁnal product was recovered by freeze drying.
4.4. Preparing and Loading Nanogels with Fluorescein. To study the release proﬁle of the loaded nanogels,
ﬂuorescein was selected as a model hydrophobic molecule to
load, through physical entrapment, because of its low detection
limit by ﬂuorescence spectroscopy. For that, the following
protocol was adopted:
First, 5 mg of HA−cys−CH was dissolved in 1 mL of
DMSO (with brief heating at 60 °C). Next, 0.5 mg of
ﬂuorescein was added in one time, followed by dropwise
addition of 5 mL of DI water. This solution was further stirred
for 1 h at RT and dialyzed against PBS buﬀer at pH 7.4
(MWCO 3500 Da, 3 L × 2) for 2 days to remove the
unencapsulated free ﬂuorescein. The loaded nanogels were
then cross-linked, as previously reported.39,62 Brieﬂy, the
solution’s pH was adjusted to ∼8.5 with 1 N NaOH, followed
by nitrogen bubbling for 10 min. DTT (163 μg, 10% relative to
the cholesterol moiety) was added, and the reaction was
allowed to proceed for 22 h. Finally, the cross-linked nanogels
were dialyzed against DI water (3 L × 2) for 2 days,
lyophilized, and stored at −20 °C before further use.
4.5. Release Proﬁle of the Loaded Nanogels.
Fluorescein release was studied with and without reducing
conditions. On one side, cross-linked nanogels (1 mg in 10 mL
of release buﬀer) were dispersed in a solution containing 10
mmol DTT and dialyzed (MWCO 6000 Da) against the same
solution (0.926 g of DTT in 600 mL of PBS). On the other
side, cross-linked nanogels (1 mg in 10 mL of release buﬀer)
were dispersed and dialyzed against the same buﬀer (600 mL
of PBS only). At various times, 10 mL from the dialysate was
taken out and replaced with the same release buﬀer volume.
Fluorescence spectroscopy was used to study the release proﬁle
of ﬂuorescein.
4.6. Carbon Dot Synthesis and Their Conjugation to
HA−Cys−CH Nanogels. Carbon dots (CD) were synthesized according to our previously reported protocol.49 A stock
solution of citric acid was ﬁrst prepared by dissolving 28.39 g
of citric acid in a volume of 220 mL of water. From this
solution, 7.34 mL was taken and added to a 100 mL beaker,
followed by adding DI water to make a total volume of 10 mL,
then 840 μL of ethylenediamine (99%) was added. The
mixture was shaken, then transferred to a microwave oven
(General Electric, 1100 W), heated for 88 s. The resulting solid
was dissolved in 3 mL of water then transferred to a 20 mL
vial. Another 2 mL of DI water was used to rinse the beaker,
and the liquid portions were combined. The solution was,
ﬁnally, dialyzed against water (MWCO 500 Da).
For CD conjugation to HA, HA−cys−CH (10 mg, 0.026
mmol) was dissolved in 4 mL of anhydrous DMSO with slight
heating at 60 °C. EDC (5 mg, 0.026 mmol), NHS (3 mg,
0.026 mmol), and carbon dots (22 mg, MW 1512 g/mol,
dissolved in 1 mL of DMSO under heating and sonication)
were all added to HA−cys−CH solution, and the mixture was
stirred at RT overnight. The product was puriﬁed by dialysis
against DI water twice and freeze-dried overnight to recover
the product as a light brown cotton-like solid.
4.7. Fluorescein-Amine Synthesis and Its Conjugation to HA−Cys−CH Nanogels. A solution of ﬂuorescein
(ﬂuorescein isothiocyanate (FITC), 100 mg, 0.257 mmol) in 3
mL of anhydrous dimethylformamide (DMF) was added

currently used methods for administering retinoid-based
compounds and, possibly, other drugs to the retina.

4. MATERIALS AND METHODS
4.1. Animals. Wild-type mice with a 129S2/Sv genetic
background were obtained from Charles River Laboratories.
Mice with a conventional knockout of the retinal pigmented
epithelium protein 65 kDa gene (Rpe65−/−) were described
previously.53 Young adult animals of either sex (5−6-week-old)
were used. Animals were provided with standard chow
(LabDiet 5053; LabDiet, Purina Mills) and maintained
under a 12 h light/12 h dark cycle. Mice were dark-adapted
overnight before physiological recordings. All experimental
protocols followed the Guide for the Care and Use of
Laboratory Animals and were approved by the Washington
University Animal Studies Committee.
4.2. Materials. Sodium hyaluronate having a molecular
weight of 10 kDa was purchased from Lifecore (Chaska, MN).
Cholesteryl chloroformate, cystamine dihydrochloride, trimethylamine, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS), anhydrous dichloromethane (DCM), and dimethyl sulfoxide
(DMSO) were all obtained from Sigma-Aldrich (St. Louis,
MO) and were used as received unless otherwise stated.
ARPE-19 (retinal pigment epithelial) cells were purchased
from American Type Culture Collection (Manassas, VA).
4.3. Synthesis of Hyaluronic Acid−Cystamine−Cholesterol Conjugate (HA−Cys−CH). The synthesis of HA−
cys−CH was conducted according to Figure 1. Initially,
cystamine dihydrochloride was neutralized as follows: 4 g of
cystamine dihydrochloride was added to 150 mL of methanol.
After stirring for 2 h at room temperature (RT), 1.5 g of
NaOH was added, and the mixture was stirred for 10 h at room
temperature. The solvent was completely removed by vacuum,
and 50 mL of anhydrous DCM was added, followed by
removing the precipitate by vacuum ﬁltration. Finally, the
solvent volume was brought to 10 mL under vacuum, and this
volume was used immediately in the next step.
In the next step, cholesteryl chloroformate (0.6 g, 1.34
mmol) and 160 μL of triethylamine were added to the
neutralized cystamine solution. The mixture was stirred at RT
for 24 h, followed by washing with 20 mL of 0.2 M aqueous
(aq) HCl once. The aqueous phase was then washed with
DCM 20 mL twice, and the combined organic phases were
washed with brine (20 mL once), dried with sodium sulfate,
and ﬁltered. Finally, dichloromethane was evaporated by a
stream of nitrogen to aﬀord the product as a pale yellow
powder (yield 85%).
Before the conjugation of cholesterol to HA, sodium
hyaluronate was converted to its acidic form to dissolve in
DMSO. This was done by dissolving sodium hyaluronate (200
mg) in 10 mL of Milli-Q water and dialyzing it (molecular
weight cut-oﬀ (MWCO) 3500 Da) against aqueous HCl (0.01
M, 1.8 L) for 20 h, followed by another dialysis against 1.8 L of
Milli-Q water for 20 h. The solution was lyophilized overnight
to yield a cotton-like solid. The molecular weights of sodium
hyaluronate and hyaluronic acid remain the same, indicating
that this conversion did not degrade the polymer (data not
shown). Next, hyaluronic acid (30 mg, 0.079 mmol) was
dissolved in 4 mL of anhydrous DMSO. To that were added
EDC (15 mg, 0.079 mmol), NHS (7.5 mg, 0.079 mmol), and
cholesterol−cystamine (CH−cys, 35.8 mg, 0.063 mmol)
previously dissolved in 2 mL of DMSO. The mixture, which
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dropwise into a solution of ethylenediamine (15 mg, 17 μL,
0.257 mmol) in 2 mL of anhydrous DMF. The reaction
mixture was stirred for 4 h at RT, followed by removing the
solvent in vacuo. The reaction product was recovered as an
orange solid and was used without further puriﬁcation.
HA−cys−CH (20 mg) was dissolved in 4 mL of DMSO at
50 °C. The solution was cooled to RT, and EDC (3 mg), NHS
(5 mg), and ﬂuorescein-amine (10 mg) were added at once.
The reaction mixture was stirred at RT overnight, followed by
dialysis (MWCO 3500 Da) against DI water to remove
unreacted reactants. The product was ﬁnally recovered by
freeze drying.
4.8. Determination of Biocompatibility of the Nanogels with ECIS. The nanogels were dispersed in Dulbecco’s
modiﬁed Eagle’s medium/Nutrient Mixture F-12 Ham
(DMEM/F-12). The in vitro biocompatibility of the nanogels
was analyzed in real time using electrical cell−substrate
impedance sensing (ECIS) by exposing ARPE-19 cells to
HA−cys−CH and HA−cys−CH/P nanogels at ﬁve diﬀerent
concentrations (0.25, 0.5, 1, 2, or 4 mg/mL). Penetratin
complexation to HA was at a weight ratio of HA/penetratin
2:1. The ARPE-19 cells were seeded at 20 000 cells/well in an
ECIS cell cultureware, a 96-well plate. The nanogel solutions
were then added at the end of 24 h of cell initial cell seeding
when a conﬂuent layer is formed (indicated by a stable
impedance signal). Eight controls per condition were used.
For the ECIS analysis, the statistical signiﬁcance was
evaluated using analysis of variance (ANOVA) to compare
the results with the respective negative control group
(untreated cells). *P < 0.05, the signiﬁcance level, was
statistically acceptable (n = 8).
ECIS is a noninvasive technique that measures the
impedance across gold electrodes at the bottom of each tissue
culture well, using a range of frequencies of alternating current.
After the initial seeding, the cells start to grow over the gold
electrodes and block the current ﬂow; as a result, the
impedance across the electrodes increases.42,63 In response to
stimuli, in this case, the nanogels, the degree to which cells are
attached to the electrodes may change. This change is reﬂected
in the impedance recordings in real time. The biocompatibility
is interpreted as the decrease or increase in impedance
compared to the negative control cells, which are not exposed
to any stimuli.
4.9. In Vitro Cellular Uptake with and without
Penetratin Complexation. The time-dependent cellular
internalization of nanogels was monitored with ARPE-19
cells using a nanoplasmonic confocal laser-scanning microscope (Leica TCS-SP8). Two laser wavelengths were used to
visualize the nucleus and the nanogels, 405 and 635 nm,
respectively, during confocal imaging.
The ARPE-19 cells were seeded in CELLview plates at 5 ×
104 cells/well for 24 h. The cells were then incubated with 2
mg/mL nanogels modiﬁed and nonmodiﬁed with the
penetratin peptide for 30 min, 1 h, 2 h, and 4 h. To complex
them with penetratin, HA−cys−CH nanogels were then mixed
with the penetratin peptide at a 2:1 weight ratio, followed by
vortexing for 30 s to yield penetratin-complexed nanogels
(HA−cys−CH/P). After each incubation time point with the
nanogels, the cells were rinsed with PBS (pH 7.4). The cells
were ﬁxed by immersion in 4% paraformaldehyde (PFA) as the
cross-linking solution for 15 min at room temperature. The
cells were washed three times with ice-cold 1× PBS for 3 min
each time. Next, the ﬁxed cells were incubated in ice-cold 1×
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PBS buﬀer containing 0.1% Triton X-100 (permeabilization
agent) for 10 min at room temperature, then washed three
times with ice-cold 1× PBS, for 5 min each time. The
CELLview plates were then incubated with the blocking buﬀer
for 30 min at room temperature. The cells were subsequently
washed three times with ice-cold 1× PBS for 3 min each time.
To stain the nuclei, SlowFade Gold Antifade Mountant with
DAPI (diluted 1:100 in 1× PBS) was used. The cells were kept
at 4 °C until confocal microscopy imaging. The cells were
washed three times with ice-cold 1× PBS for 5 min each time
before being transferred to the confocal microscope for visual
analyses.
4.10. Loading Nanogels with 9-cis-Retinal. As a proof
of concept, 9-cis-retinal, a readily available and a more stable
form of the natural visual chromophore 11-cis-retinal, was
loaded into HA−cys−CH, as described above for ﬂuorescein.
The loading content of 9-cis-retinal inside the nanogels was
determined by UV−vis spectroscopy (after determination of
λmax = 378 nm of 9-cis-retinal in DMSO). A standard curve was
derived from various concentrations of 9-cis-retinal in DMSO.
4.11. Ex Vivo ERG Recordings from Isolated Mouse
Retinas. Mice were dark-adapted overnight, sacriﬁced by CO2
asphyxiation, and a whole retina was removed from each
mouse eyecup under infrared illumination. The retina was
mounted on a ﬁlter paper with the photoreceptor side up and
placed in a perfusion chamber between two electrodes
connected to a diﬀerential ampliﬁer. The tissue was perfused
with Locke’s solution containing 112.5 mM NaCl, 3.6 mM
KCl, 2.4 mM MgCl2, 1.2 mM CaCl2, 10 mM N-(2hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES),
pH 7.4, 20 mM NaHCO3, 3 mM Na succinate, 0.5 mM Na
glutamate, 0.02 mM ethylenediaminetetraacetic acid (EDTA),
and 10 mM glucose. This solution was supplemented with 2
mM L-glutamate and 10 μM DL-2-amino-4-phosphonobutyric
acid (DL-AP4) to block postsynaptic components of the
photoresponse64 and with 20 μM BaCl2 to suppress the slow
glial PIII component.65 MEM vitamins and MEM amino acid
solutions (Sigma) were also added to improve retina viability.
The perfusion solution was continuously bubbled with a 95%
O2/5% CO2 mixture and heated to 36−37 °C.
Light stimulation was applied in 20 ms test ﬂashes of
calibrated 505 nm light-emitting diode (LED) light. The
stimulating light intensity was controlled by a computer in 0.5
log unit steps. Intensity−response relationships were ﬁtted
with Naka-Rushton hyperbolic functions, as follows

R=

R max ·I n
n
I n + I1/2

where R is the transient-peak amplitude of the response, Rmax is
the maximal response amplitude, I is the ﬂash intensity, n is the
Hill coeﬃcient (exponent), and I1/2 is the half-saturating light
intensity. Photoresponses were ampliﬁed by a diﬀerential
ampliﬁer (DP-311, Warner Instruments), low-pass ﬁltered at
30 Hz (8-pole Bessel), digitized at 1 kHz, and stored on a
computer for further analysis. Data were analyzed with
Clampﬁt 10.4 and Origin 8.5 software. Data were expressed
as means ± SEM and analyzed using the independent twotailed Student’s t-test, with an accepted signiﬁcance level of P <
0.05.
4.12. Acute Application of 9-cis-Retinal-Loaded
Nanogels to Mouse Retinas. HA−cys−CH nanogels (1.5
g, containing ∼300 μg of 9-cis-retinal) and 0.75 mg of the
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interactions. Nanogels (20 μL) were applied topically to the
right eye of each dark-adapted anesthetized Rpe65−/− mouse
placed on a heating pad of the ERG apparatus. The procedure
was then repeated twice, at 20 and 50 min since the beginning
of the ﬁrst application (10 μL of nanogels was used at these
time points), and in vivo ERG recordings were performed after
an additional hour, as above. Thus, a total volume of 40 μL of
nanogels (or PBS) was applied to each eye. In control
experiments, the equivalent amount of either 9-cis-retinalloaded HA−cys−CH nanogels without penetratin, or free 9cis-retinal in PBS, was applied to the mouse right eye under the
same treatment regimen. During these manipulations (∼2 h),
the body temperature of the mouse was maintained at 37 °C
with a heating pad, and the anesthesia was repeated every 30−
40 min, with ∼1/2 of the initial dose of ketamine.

penetratin peptide were suspended thoroughly in 8 mL of L15
cell culture solution (13.6 mg/mL, pH 7.4, Sigma) containing
1% bovine serum albumin (BSA), in the dark. The ﬁnal
concentration of the retinoid was estimated to be ∼130 μM. A
whole mouse retina on the ﬁlter paper was incubated in a Petri
dish with 2−2.5 mL of this oxygenated solution for 3.5−4 h in
the dark at RT. Control retina from the second mouse eye was
incubated 3.5−4 h in the same L15 solution without nanogels
and retinoid. In a separate control experiment, an equivalent
amount of 9-cis-retinal in L15 (∼130 μM, dissolved in 0.1%
EtOH) was applied to the retina for 1 h. The tissue was then
transferred to the perfusion chamber for ex vivo ERG
recordings, as described above.
4.13. Topical Application of Fluorescein-Conjugated
Nanogels. With the room lights oﬀ, 20 μL of the prepared
penetratin-complexed nanogel solution in 1× PBS (0.5 mg/
mL) was instilled on the right eye of each live unanesthetized
wild-type mouse, and an equal volume of control samples from
either ﬂuorescein solution only or PBS solution was applied to
its left eye. The animal was immediately placed on the top part
of a standard cage. Its tail was handled gently for 15 min to
restrict the freedom of the animal’s movement and prevent it
from removing the solutions from the eyes. After visible
inﬁltration of most of the solutions into the eyes, the mouse
was allowed to move freely in its cage for another 15 min. The
animal was then sacriﬁced by CO2 asphyxiation, and both eyes
were quickly removed and ﬁxed for immunohistochemistry.
Next, the eyes were ﬁxed in 4% paraformaldehyde for 24 h and
then processed routinely through graded alcohol and cleared
with xylenes and inﬁltrated through four changes of paraﬃn.
The eyes were embedded in a sagittal manner. The samples
were cut at 4 μm on a rotary microtome, and slides were dried
for 30 min at 60 °C. The slides were deparaﬃnized in xylenes
and rehydrated through a series of graded alcohol. After rinsing
well in distilled water, the slides were washed with PBS and
coverslipped with VECTASHIELD HardSet Mounting Medium with DAPI. The VECTASHIELD mounting medium was
from Vector Laboratories. Finally, the slides were visualized
under a confocal microscope (Zeiss LSM800) to investigate
nanogel’s distribution in the eye.
4.14. In Vivo ERG Analysis. Dark-adapted Rpe65−/− mice
were anesthetized with an intraperitoneal injection of a mixture
of ketamine (100 mg/kg) and xylazine (20 mg/kg). Pupils
were dilated with a drop of 1% atropine sulfate. Mouse body
temperature was maintained at 37 °C with a heating pad. ERG
responses were recorded from both eyes by corneal contact
electrodes held in place by a drop of Gonak solution. Full-ﬁeld
ERGs were performed with the UTAS BigShot apparatus
(LKC Technologies, Gaithersburg, MD) using Ganzfeldderived test ﬂashes of calibrated green 530 nm LED light
(within a range from 0.75 to 23.5 cd s/m2) or white light
generated by the Xenon ﬂash tube (from 80.7 to 700 cd s/m2).
Both ERG a-waves and b-waves were measured. Data were
expressed as means ± SEM and analyzed using the
independent two-tailed Student’s t-test, with an accepted
signiﬁcance level of P < 0.05.
4.15. Topical Application of 9-cis-Retinal-Loaded
Nanogels. An aliquot of 1 mg of 9-cis-retinal-loaded HA−
cys−CH nanogels was suspended in 2 mL of 1× PBS in the
dark. The suspension was sonicated brieﬂy and shaken to
disperse the nanogels. Nanogels were then mixed with the
penetratin peptide at a 2:1 weight ratio, followed by vortexing
for 30 s to complex HA with penetratin via electrostatic
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(49) Karakoçak, B. B.; Liang, J.; Kavadiya, S.; Berezin, M. Y.; Biswas,
P.; Ravi, N. Optimizing the Synthesis of Red-Emissive NitrogenDoped Carbon Dots for Use in Bioimaging. ACS Appl. Nano Mater.
2018, 1, 3682−3692.
(50) Znoiko, S. L.; Rohrer, B.; Lu, K.; Lohr, H. R.; Crouch, R. K.;
Ma, J. X. Downregulation of cone-specific gene expression and
degeneration of cone photoreceptors in the Rpe65-/- mouse at early
ages. Invest. Ophthalmol. Visual Sci. 2005, 46, 1473−1479.

Article

(51) Zhang, H.; Fan, J.; Li, S.; Karan, S.; Rohrer, B.; Palczewski, K.;
Frederick, J. M.; Crouch, R. K.; Baehr, W. Trafficking of membraneassociated proteins to cone photoreceptor outer segments requires the
chromophore 11-cis-retinal. J. Neurosci. 2008, 28, 4008−4014.
(52) Rohrer, B.; Lohr, H. R.; Humphries, P.; Redmond, T. M.;
Seeliger, M. W.; Crouch, R. K. Cone opsin mislocalization in
Rpe65-/- mice: a defect that can be corrected by 11-cis retinal. Invest.
Ophthalmol. Visual Sci. 2005, 46, 3876−3882.
(53) Redmond, T. M.; Yu, S.; Lee, E.; Bok, D.; Hamasaki, D.; Chen,
N.; Goletz, P.; Ma, J. X.; Crouch, R. K.; Pfeifer, K. Rpe65 is necessary
for production of 11-cis-vitamin A in the retinal visual cycle. Nat.
Genet. 1998, 20, 344−351.
(54) Kolesnikov, A. V.; Tang, P. H.; Kefalov, V. J. Examining the
Role of Cone-expressed RPE65 in Mouse Cone Function. Sci. Rep.
2018, 8, No. 14201.
(55) Kolesnikov, A. V.; Kefalov, V. J. Transretinal ERG recordings
from mouse retina: rod and cone photoresponses. J. Visualized Exp.
2012, 61, No. e3424.
(56) Fan, J.; Woodruff, M. L.; Cilluffo, M. C.; Crouch, R. K.; Fain,
G. L. Opsin activation of transduction in the rods of dark-reared
Rpe65 knockout mice. J. Physiol. 2005, 568, 83−95.
(57) Hurley, J. B.; Ebrey, T. G.; Honig, B.; Ottolenghi, M.
Temperature and wavelength effects on the photochemistry of
rhodopsin, isorhodopsin, bacteriorhodopsin and their photoproducts.
Nature 1977, 270, 540−542.
(58) Sparrrow, J. R.; Hicks, D.; Hamel, C. P. The Retinal Pigment
Epithelium in Health and Disease. Curr. Mol. Med. 2011, 11, 802−
823.
(59) Pescina, S.; Ostacolo, C.; Gomez-Monterrey, I. M.; Sala, M.;
Bertamino, A.; Sonvico, F.; Padula, C.; Santi, P.; Bianchera, A.; Nicoli,
S. Cell penetrating peptides in ocular drug delivery: State of the art. J.
Controlled Release 2018, 284, 84−102.
(60) Varela-Fernández, R.; Diaz-Tome, V.; Luaces-Rodriguez, A.;
Conde-Penedo, A.; Garcia-Otero, X.; Luzardo-Alvarez, A.; FernandezFerreiro, A.; Otero-Espinar, F. J. Drug Delivery to the Posterior
Segment of the Eye: Biopharmaceutic and Pharmacokinetic
Considerations. Pharmaceutics 2020, 12, No. 269.
(61) Nickell, S.; Park, P. S. H.; Baumeister, W.; Palczewski, K.
Three-dimensional architecture of murine rod outer segments
determined by cryoelectron tomography. J. Cell Biol. 2007, 177,
917−925.
(62) Meng, F. H.; Hennink, W. E.; Zhong, Z. Reduction-sensitive
polymers and bioconjugates for biomedical applications. Biomaterials
2009, 30, 2180−2198.
(63) Liang, J.; Karakocak, B.; Struckhoff, J.; Ravi, N. Synthesis and
Characterization of Injectable Sulfonate-Containing Hydrogels.
Biomacromolecules 2016, 17, 4064−4074.
(64) Sillman, A. J.; Ito, H.; Tomita, T. Studies on the mass receptor
potential of the isolated frog retina. I. General properties of the
response. Vision Res. 1969, 9, 1435−1442.
(65) Nymark, S.; Heikkinen, H.; Haldin, C.; Donner, K.;
Koskelainen, A. Light responses and light adaptation in rat retinal
rods at different temperatures. J. Physiol. 2005, 567, 923−938.

6184

https://dx.doi.org/10.1021/acsomega.0c05535
ACS Omega 2021, 6, 6172−6184

